yahoo.comSEP 161 min read$MCK

Alluvium Raised Its McKesson (MCK) Stake as Long-Term Growth Expectations Remain Strong

Alluvium Asset Management increased its stake in McKesson (MCK) due to strong long-term growth expectations. McKesson's stock was down 12.6% in the quarter but reported earnings in line with expectations. The company provided strong guidance for next year's earnings. McKesson's stock price is $899.56, with a 52-week gain of 29.95%.

Original reporting

yahoo.com

Published Sep 16, 2026, 3:45 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Sep 16, 2026, 4:38 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

Alluvium Raised Its McKesson (MCK) Stake as Long-Term Growth Expectations Remain Strong — source image — Source · yahoo.com

Decision brief

The 30-second read

$MCKBullishLow

Why it matters

The fund's increased valuation and stake in McKesson provide a fresh endorsement but are unlikely to drive a large price move.

Market read

A modest fund buying signal for MCK; limited broader market impact.

What to watch

Fund's overall underperformance and currency losses could offset any benefit to MCK.

Relevance 4/10Novelty 5/10Timing: post-release

Background

Alluvium Asset Management released its Q2 2026 investor letter, noting a shift to equity rally and mixed portfolio performance.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$MCKBullishMedium confidence

Context

Alluvium Global Fund raised its valuation of McKesson by 18% and increased its stake to 6.8% after the fund's Q2 2026 letter.

Expected impact

Potential modest upside as the market digests the increased ownership.

Evidence & confidence

The fund's valuation lift and additional purchase are new information, but the size of the stake change is modest relative to market cap.

Market effects

Sector

Healthcare distribution sector may see slight positive sentiment from fund endorsement.

Regional

U.S. healthcare services market sees minor uplift.

Global

Limited; primarily U.S. investors.

Counterpoint

What could challenge this read

Fund's increased stake may be premature if broader healthcare margins soften.

Key entities

Asset Manager
Alluvium Asset Management
Manager of the Conventum – Alluvium Global Fund.
Company
McKesson Corporation
Healthcare services and drug distribution company.

Read at source ← All news

SEP 15

$MCKMed

Does Raised EPS Guidance Change The Bull Case For McKesson Stock (MCK)?

McKesson (MCK) raised its full-year EPS guidance to 13-15% (15-17% excluding prior-year items) and plans to rebrand its Medical-Surgical unit as Wellverse, targeting an IPO in 2H 2027. The company also aims to acquire Precision Medicine Group to expand oncology and biopharma services. Management highlights core operations are tracking ahead, but structural pressures on drug pricing and high leverage remain risks. McKesson projects $502.2B revenue and $6.3B earnings by 2029, implying 6.9% yearly

simplywall.st3 min

SEP 14

$MCKHigh

McKesson Raises Outlook, Eyes Oncology Growth With Precision Medicine Deal

McKesson (MCK) raised its outlook, citing growth in its Oncology & Multispecialty segment, which saw 33% revenue growth and 41% adjusted operating profit growth in Q1. The company also announced a deal for Precision Medicine Group, expected to be strategically and financially accretive. McKesson's RxTS segment grew 9% in revenue and 13% in adjusted operating profit, with GLP-1-related business accounting for 11% of its revenue. The company plans to invest more in growth, automation, and technolo

yahoo.com2 min

SEP 8

$MCKMed

McKesson Eyes $2.25B Precision Medicine Deal as Oncology Growth Accelerates

McKesson (MCK) plans a $2.25B precision medicine acquisition, expecting strategic alignment and value creation. Q1 revenue grew 5% in North American Pharmaceutical Distribution and 33% in Oncology. The company aims to return $5B to shareholders this year, including $2.5B in share repurchases and a 15% dividend increase. McKesson also expects to separate its Medical-Surgical business, rebranded as Wellverse, by late 2024.

yahoo.com6 min

SEP 7

$CAHMedAI 8/10

4 companies on verge of settling US opioid lawsuits

AmerisourceBergen, Cardinal Health, McKesson, and Johnson & Johnson are nearing a $26B settlement for opioid lawsuits. New York reached a separate $1B deal with the distributors. Johnson & Johnson will contribute up to $5B nationally. Trials continue elsewhere.

pressdemocrat.com3 min

SEP 6

$MCKMedAI 8/10

McKesson Bets $2.25 Billion More on Oncology With Precision Medicine Buy

McKesson (NYSE:MCK) to acquire Precision Medicine Group for $2.25B, expanding its oncology and specialty care business. The deal aims to enhance clinical research and commercialization services, with Precision Medicine joining McKesson's Oncology & Multispecialty segment. McKesson has been divesting non-core assets to fund such investments, and the Oncology segment saw 33% revenue growth in Q1 2026. However, the deal's timeline and integration risks remain uncertain.

yahoo.com3 min

SEP 5

$MCKHighAI 8/10

McKesson Stock: Is MCK Outperforming the Healthcare Sector?

McKesson (MCK), a $107.4B healthcare distributor, has outperformed the sector, rising 24.6% in 3 months and 33.4% in 52 weeks. Q1 2027 revenue hit $105.4B, up 7.7% YoY, with adjusted EPS of $9.93. The company raised full-year EPS guidance to $44.60. Analysts rate MCK a 'Strong Buy' with a $984.29 price target.